ArticleScience translational medicine2017
Therapeutic targeting of PGBD5-induced DNA repair dependency in pediatric solid tumors.
Open access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 62 citations in OpenAlex.
- Unlocking catalytic asymmetric transformations of sulfilimidoyl fluorides toward chiral sulfinimidate esters.Chemical science · 2026Article
- Targeted and molecular therapies in Ewing sarcoma: a comprehensive review of preclinical and clinical advances.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Relapsed rhabdoid tumours and other non-nephroblastoma childhood and adolescent kidney tumours: perspectives from the HARMONICA collaboration.Nature reviews. Urology · 2026Review
- FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy.Cancer research · 2026Article
- A transposase-derived gene required for human brain development.Science advances · 2026Article
- Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomas.The Journal of clinical investigation · 2025Article
- ThebioRxiv : the preprint server for biology · 2025Article
- Histone Deacetylase Inhibitors Target DNA Replication Regulators and Replication Stress in Ewing Sarcoma Cells.Cancer research communications · 2025Article
- CHST3, PGBD5, and SLIT2 can be identified as potential genes for the diagnosis and treatment of osteoporosis and sarcopenia.Scientific reports · 2025Article
- ACR-368, a CHK1/2 Kinase Inhibitor, in Patients With Relapsed or Refractory Desmoplastic Small Round Cell Tumor: Phase I/II Trial Results.JCO oncology advances · 2025Article
- Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models.Molecular cancer therapeutics · 2024Article
- Childhood cancer mutagenesis caused by transposase-derived PGBD5.Science advances · 2024Article
- Passenger Gene Coamplifications Create Collateral Therapeutic Vulnerabilities in Cancer.Cancer discovery · 2024Article
- Passer, a highly active transposon from a fish genome, as a potential new robust genetic manipulation tool.Nucleic acids research · 2023Article
- Synthesis of Sulfoximines and Sulfonimidamides Using Hypervalent Iodine Mediated NH Transfer.Molecules (Basel, Switzerland) · 2023Review
- Synthesis of Sulfoximine Propargyl Carbamates under Improved Conditions for Rhodium Catalyzed Carbamate Transfer to Sulfoxides.The Journal of organic chemistry · 2022Article
- Therapeutic targeting of ATR in alveolar rhabdomyosarcoma.Nature communications · 2022Article
- Novel Targeted Therapeutic Strategies for Ewing Sarcoma.Cancers · 2022Review
- Perspective on the Use of DNA Repair Inhibitors as a Tool for Imaging and Radionuclide Therapy of Glioblastoma.Cancers · 2022Review
- ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib.Cancer research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 6 institutions in 3 countries.
Anton G HenssenMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID http://orcid.org/0000-0003-1534-778X
Casie ReedMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Eileen JiangMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID http://orcid.org/0000-0003-0853-2944
Heathcliff Dorado GarciaDepartment of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany.ORCID http://orcid.org/0000-0002-2578-3350
Jennifer von StebutDepartment of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany.
Ian C MacArthurMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Patrick HundsdoerferBerlin Institute of Health, 10178 Berlin, Germany.
Jun Hyun KimMolecular Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID http://orcid.org/0000-0003-0196-8796
Elisa de StanchinaAntitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID http://orcid.org/0000-0002-3873-315X
Yasumichi KuwaharaDepartment of Biochemistry and Molecular Biology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Hajime HosoiDepartment of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Neil J GanemSection of Hematology and Medical Oncology, Department of Pharmacology, Boston University School of Medicine, Boston, MA 02215, USA.ORCID http://orcid.org/0000-0003-0269-6585
Filemon Dela CruzDepartment of Pediatrics, Weill Cornell Medical College of Cornell University and Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID http://orcid.org/0000-0002-8356-5191
Andrew L KungDepartment of Pediatrics, Weill Cornell Medical College of Cornell University and Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID http://orcid.org/0000-0002-9091-488X
Johannes H SchulteBerlin Institute of Health, 10178 Berlin, Germany.
John H PetriniMolecular Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID http://orcid.org/0000-0001-5102-5679
Alex KentsisMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. kentsisresearchgroup@gmail.com.ORCID http://orcid.org/0000-0002-8063-9191
Memorial Sloan Kettering Cancer Center · USCharité - Universitätsmedizin Berlin · DEKyoto Prefectural University of Medicine · JPBerlin Institute of Health at Charité - Universitätsmedizin Berlin · DEBoston University · USGerman Cancer Society · DE
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MRegulation of the DNA damage response by the Mre11 complexR37GM059413 · NIGMS · SLOAN-KETTERING INST CAN RESEARCH · PI PETRINI, JOHN HJ · 2012 to 2020
$5.2MThe Mre11 complex: linking recombination to checkpointsR01GM059413 · NIGMS · UNIVERSITY OF WISCONSIN MADISON · PI PETRINI, JOHN HJ · 1999 to 2011
$5.2MStructure and function of genome plasticity in human cancerR01CA214812 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI KENTSIS, ALEX · 2018 to 2022
$2.5MAberrant activation of HGF/MET signaling as a therapeutic target in AMLK08CA160660 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI KENTSIS, ALEX · 2011 to 2015
$768kFASEB SRC on Genetic Recombination and Genome RearrangementsR13CA162528 · NCI · FEDERATION OF AMER SOC FOR EXPER BIOLOGY · PI PETRINI, JOHN HJ · 2011 to 2011
$5kNCI NIH HHS K08 CA160660NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA214812NCI NIH HHS R13 CA162528NIGMS NIH HHS R01 GM059413NIGMS NIH HHS R37 GM059413
Abstract
Despite intense efforts, the cure rates of childhood and adult solid tumors are not satisfactory. Resistance to intensive chemotherapy is common, and targets for molecular therapies are largely undefined. We have found that the majority of childhood solid tumors, including rhabdoid tumors, neuroblastoma, medulloblastoma, and Ewing sarcoma, express an active DNA transposase,
Indexed as
Molecular Targeted TherapyAnimalsApoptosisCell Line, TumorChildDNA DamageDNA End-Joining RepairDNA RepairDrug SynergismHumansIndolesMiceMice, NudeModels, BiologicalMorpholinesNeoplasmsceralasertibIndolesMorpholinesPGBD5 protein, humanPyrimidinesSulfonamidesSulfoxidesTransposases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.